All In Biotech

Free tool

FAERS Monitor: Vizamyl

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203137 or its brand name (Vizamyl, Flutemetamol F-18). Reports on generic versions are filed under their own applications.

Reports

520

Serious

166

32% of reports

Hospitalization

30

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • flushing265
  • dyspnoea140
  • back pain120
  • dizziness91
  • nausea87
  • chest discomfort62
  • headache51
  • chest pain46
  • cough39
  • erythema39
  • feeling hot37
  • hot flush29
  • hyperhidrosis28
  • blood pressure increased27
  • muscle spasms27

Reports by year received

View as table
YearReports
20174
20187
201913
20207
20217
20227
202315
202476
2025199
2026185

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,639 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
flushingSignal265105.797.127,442
chest discomfortSignal6224.519.41,380
feeling hotSignal3724.417.9810
back painSignal12020.917.92,278
hot flushSignal2915.610.9382
chest painSignal4610.07.6369
dyspnoeaSignal14010.08.71,157
hyperhidrosisSignal288.86.1187
erythemaSignal397.75.7222
dizzinessSignal917.46.1508
blood pressure increasedSignal277.14.9138
muscle spasmsSignal276.04.1107
coughSignal395.64.2146
nauseaSignal874.43.7238
headacheSignal513.32.581

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.